In a study focused on HER2-positive advanced breast cancer treated with trastuzumab-pertuzumab therapy, a high baseline pan-immune-inflammation value (PIV) was associated with poor prognosis, rather than MLR, NLR, and PLR (24). Here, ERBB2 is linked to breast carcinoma.